Delayed Presentation of Meconium Ileus in an Infant With Cystic Fibrosis

Thomas Lahiri1,2, Jillian S Sullivan3,2, Kennith H Sartorelli2,4

  • 1Departments of Pediatrics and thomas.lahiri@uvmhealth.org.

Pediatrics
|September 26, 2020
PubMed

Insights

Delayed diagnosis of cystic fibrosis (CF) in infants can lead to severe complications like bowel perforation. Early detection through monitoring meconium output is crucial while awaiting newborn screening (NBS) results for CF.

Area of Science:

  • Pediatrics
  • Genetics
  • Gastroenterology

Background:

  • Meconium ileus, a common early sign of cystic fibrosis (CF), often leads to delayed diagnosis pending newborn screening (NBS).
  • Infants typically present with symptoms shortly after birth, but diagnosis can be postponed.

Observation:

  • A case of an 11-day-old infant with delayed meconium passage is presented.
  • The infant initially showed no distress but later developed an acute abdomen, shock, bowel perforation, and peritonitis, requiring surgery.
  • Newborn screening for CF was positive, confirming the diagnosis via mutation analysis.

Findings:

  • Delayed diagnosis of CF, due to subtle initial symptoms and awaiting NBS results, led to critical illness.
  • The infant's condition necessitated prolonged parenteral nutrition and mechanical ventilation.
  • Lipid management with a soy, MCT, olive, and fish oil blend resulted in transient transaminitis without cholestasis, with spontaneous normalization.

Implications:

  • Delayed meconium passage and decreased stool output in newborns warrant heightened suspicion for CF, prompting further evaluation alongside NBS.
  • Close monitoring is essential to prevent life-threatening complications in infants with suspected CF.
  • Proactive use of specific lipid formulations during prolonged parenteral nutrition may prevent cholestasis in high-risk infants.

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
601
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
332
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
550